產(chǎn)品屬性：
產(chǎn)品名稱(chēng) | TW9 |
規(guī)格 | 1mg、5mg |
貨號(hào) | EY-01Y12648 |
Cas No.: N/A
別名: N/A
化學(xué)名: N/A
分子式: C32H28ClN7O2S
分子量: 610.1
溶解度: DMF: 20 mg/ml,DMSO: 10 mg/ml
儲(chǔ)存條件: -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μM, respectively).1 It is selective for BD2 over BD1 in BRD4 (IC50 = 0.72 μM) and for HDAC1 over HDAC2 (IC50 = 2.5 μM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1 phase in HPAC pancreatic cancer cells when used at a concentration of 2 μM. TW9 acts synergistically with gemcitabine to reduce the viability of HPAC cells.1.Zhang, X., Zegar, T., Weiser, T., et al.Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinomaInt. J. Cancer147(10)2847-2861(2020)
特別提醒公司產(chǎn)品僅供科研使用
